Alyssa Walker

Mrs. Alyssa Walker

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Randall T. LoderRandall T. Loder
Randall T. Loder
AWAlyssa Walker
Alyssa Walker
LBLaurel Blakemore
Laurel Blakemore
Background/Objectives: Equestrian activities can result in spine injuries. Most studies are from single centers, and none use a national database. It was the purpose of this study to describe the demographics, injury mechanisms, and types of equestrian-associated spinal injuries using a US national ED database. Methods: The National Electronic Injury Surveillance System database was queried for equestrian-related spine injuries from 2000–2023. ED disposition was categorized as discharged or not discharged. Statistical analyses accounted for the weighted, stratified nature of the data to obtain national estimates. Results: There were an estimated 54,830 patients, having an average age of 42 years. Most were female (73.6%) and White (93.7%); one-half (51.1%) were not discharged from the ED. The spine level was the lumbar (49.1%), thoracic (24.4%), sacrococcygeal (15.5%), and cervical (11.0%) spine. Multiple spine fractures occurred in 4.0%. A simple fall off a horse occurred in 53.6% of the injuries, and the patient was bucked/thrown/kicked off the horse in 39.7%. Neurologic injury was rare (1.8%). Hospital admission was highest in the cervical group (74.3%) and lowest in the sacrococcygeal group (33.5%). The cervical group had the highest percentage of males (43.7%) compared to the thoracic, lumbar, and sacrococcygeal groups (22.8%, 27.3%, 16.8%, respectively). There were proportionally fewer females in those over 50 years of age, where the male percentage was 11.7%, 25.6%, and 31.6% for those 50 years old, respectively. Conclusions: This large study can be used as baseline data to evaluate further changes in equestrian injuries, especially the impact of further prevention strategies, education protocols, and legislative/governmental regulations of public equestrian localities.

27 November 2024 in Children
Verified
Journal Article
Open access
PDF file
Randall T. LoderRandall T. Loder
Randall T. Loder
AWAlyssa Walker
Alyssa Walker
LBLaurel Blakemore
Laurel Blakemore
Background: Fractures often occur due to equestrian activities with injury patterns varying by age. The purpose of this study was to investigate in detail fracture patterns and associated demographics in children due to equine activities. Materials: The US National Electronic Injury Surveillance System was queried for all injuries with the consumer product code 1239 (horseback riding) from 2000 to 2023. Those <16 years old with fractures were extracted. Statistical analyses were performed with SUDAAN 11.0.01™ software to obtain national estimates. Results: There were an estimated 101,677 patients with a fracture. Girls comprised 72.5% and the patient was discharged from the hospital in 81.5% of cases. Fractures involved the upper extremity in 80,973 (80.0%), the pelvis/lower extremity in 11,794 (11.7%), the spine in 3060 (3.0%), the skull/face in 4321 (4.4%), and the rib/sternum in 940 (0.9%). The humerus, elbow, radius/ulna, and wrist accounted for 62.4% of all the fractures. The youngest age group (0- to 5-year-olds) had more boys and was more likely to be admitted to the hospital. The child was injured due to a fall from the horse in 75.7%, bucked/thrown off/kicked off in 17.0%, with the remaining 7.3% from other mechanisms. Conclusions: This extensive description of fractures in children due to equestrian injuries can be used to determine the effectiveness of future prevention strategies, such as protective equipment and educational programs. It also gives pediatric trauma and orthopedic surgeons an overall view of the types of fractures which occur in children due to equestrian activities.

6 August 2025 in Wilderness & Environmental Medicine
Verified
Journal Article
Closed access
Randall T. LoderRandall T. Loder
Randall T. Loder
AWAlyssa Walker
Alyssa Walker
LBLaurel Blakemore
Laurel Blakemore
Introduction: Amputations and avulsion injuries due to horse-associated activity are rare, yet they can result in significant impairment. The purpose of this study was to further investigate such injuries using a national emergency department database. Methods: The US National Electronic Injury Surveillance System (NEISS) was used to identify horse-associated amputation and avulsion injuries occurring between 2000–2023. Demographic data of age, sex, and injury details were collected. Results: There were 34,091 emergency department visits for equine-associated injuries, with 120 (0.35%) due to amputations/avulsions; 53 (44%) patients sustained amputations, and 67 patients (56%) sustained avulsions. The average age was 37 (SD = 21 years). There were 78 female and 42 male patients. The most common mechanism of injury was riding the horse, with further details not specified (31%), followed by equipment issues (19%), bucked/thrown/kicked off the horse (15%), falling off the horse (11%), and others (6%). A rope/chain was involved in 29 patients (24%). There were 55 amputations involving the finger (40), thumb (13), and others (2). Rope-related injuries were more commonly involved in those sustaining amputations versus avulsions (42% vs 10%, P < .001). Males had more rope-associated injuries (36% vs 18%, P = .043). Conclusions: This is the largest study to date of amputations and/or avulsions due to horse-associated injuries. There were multiple mechanisms of injury, with ropes involved in one-quarter. This baseline data can be useful for evaluating the effectiveness of future prevention programs.

15 September 2025 in Cancer Research Communications
Verified
Journal Article
Open access
ESEmily E. Seiden
Emily E. Seiden
SRSpencer M. Richardson
Spencer M. Richardson
LELeah A. Everitt
Leah A. Everitt
GKGabrielle J. Knafler
Gabrielle J. Knafler
AWAlyssa Walker
Alyssa Walker
EGEdward M. Greenfield
Edward M. Greenfield
Osteosarcoma is the most common primary malignant bone tumor and predominantly affects adolescents and young adults. It is the third most common cause of cancer-related deaths among 9-24-year-olds. Despite aggressive chemotherapeutic and surgical therapies, the survival rate is only 25% for patients with detectable lung metastases at diagnosis and only 70% in patients that present without detectable lung metastases. The poor prognosis is due to growth of metastases irrespective of whether they are initially large enough to detect clinically. It is therefore necessary to develop new methods to target the growth of lung micrometastases. An NCI panel of FDA approved oncology drugs was therefore screened using three highly metastatic human osteosarcoma cell lines. To more closely approximate in vivo micro-metastases, the screen used a 3D multicellular in vitro osteosarcoma spheroid (sarcosphere) model. Among 13 hits from the initial screen, we identified the histone deacetylase inhibitor (HDI) romidepsin as the most promising inhibitor in secondary screens comparing effects on sarcospheres to clinically achievable levels and to effects on non-transformed cells. Romidepsin potency was evident with and without standard-of-care chemotherapeutics (MAP: Methotrexate, Adriamycin, Cisplatin) at romidepsin concentrations that are clinically achievable and did not affect non transformed cells. Romidepsin also substantially outperformed the other three FDA approved HDIs and eight HDIs in clinical trials. The effects of romidepsin were a transient cell cycle block at G2/M and cell death. Importantly, sarcospheres derived from ~30% of human and 50% of canine patient samples responded to romidepsin at clinically tolerable concentrations (ED50s<70nM).

31 December 2024 in Proceedings of IMPRS
Verified
Journal Article
Open access
PDF file
AWAlyssa Walker
Alyssa Walker
ESEmily Seiden
Emily Seiden
PWPiper Wilburn
Piper Wilburn
EGEd Greenfield
Ed Greenfield
Background:Osteosarcoma, the most prevalent primary bone cancer, disproportionally affects adolescents and young adults. Despite aggressive chemotherapeutics, prognosis remains poor, highlighting the need for novel therapeutics. Romidepsin, a histone deacetylase inhibitor, emerged as exceptionally potent and minimally toxic in our screen of 114 FDA-approved oncology drugs using three-dimensional osteosarcoma spheroids (sarcospheres). Due to the genetic complexity of pathogenesis, differences in sensitivity exist across cell lines and patient samples. Understanding the mechanism of romidepsin is crucial for determining predictability of treatment response, especially considering its short half-life and weekly administration regimen. Methods:Sarcospheres derived from established cell lines (LM7, MG63.3, and 143B) or patient sample (TT2) were exposed to various concentrations of romidepsin for 24 hours. Metabolic activity was measured by resazurin reduction assays at multiple timepoints following romidepsin removal. Results:Effects of transient romidepsin exposure last at least 14 days. TT2 and LM7 sarcospheres do not increase in size over 48 hours of culture, and recovery is prevented at clinically achievable levels. In contrast, 143B and MG63.3 sarcospheres show growth over 48 hours and romidepsin blocks this growth. For these sarcospheres, concentrations above clinically achievable levels are required to prevent recovery. Conclusions and Potential Impact:Romidepsin is FDA-approved for weekly administration in lymphoma. Effects caused by transient exposure to romidepsin persisted for 14 days in slow growing patient-derived sarcospheres, suggesting weekly administration is likely sufficient for patients with osteosarcoma. Results of this study are consistent with our previous findings that there are two types of responses to romidepsin. Romidepsin causes a G2 cell cycle block and growth inhibition in 143B and MG63.3 sarcospheres, while it causes DNA damage and cell death in LM7 and TT2 sarcospheres. Further exploration of these mechanistic differences has the potential to personalize medicine by providing better predictability of response to treatment and insight into prognosis.

15 October 2025
Verified
Other
Open access
ESEmily E. Seiden
Emily E. Seiden
SRSpencer M. Richardson
Spencer M. Richardson
LELeah A. Everitt
Leah A. Everitt
GKGabrielle J. Knafler
Gabrielle J. Knafler
AWAlyssa Walker
Alyssa Walker
EGEdward M. Greenfield
Edward M. Greenfield
Toxicity and therapeutic indices on Small Airway Epithelial Cells